Two homologs of the tumor suppressor p53, named p63 and p73, are each expressed from at least two start sites of mRNA synthesis, yielding full-length, transactivating (TA) isoforms, and also aminoterminally truncated (DN) isoforms that act as antagonists to p53. The expression of TAp73-transcripts is induced by E2F and negatively regulated by transforming growth factor b (TGFb). The DNp73 promoter is induced by p53, resulting in negative feedback to control p53 activity. Here, we have analysed the expression of p63 in comparison with p73. In contrast to the induction of DNp73, the expression of DNp63 was reduced by p53 particularly in human keratinocytes, at the mRNA and protein levels. Accordingly, the 3 0 promoter of p73, but not that of p63, was activated by p53 in reporter assays. DNp73 mRNA and DNp73 protein, but not the p63 gene products, also accumulated when HaCat cells (lacking functional p53) were grown to high density. TAp73, but not TAp63, expression was suppressed by TGFb in these cells, and the TAp73, but not the TAp63, promoter was induced by E2F-1. Thus, in contrast to the functional similarities of their respective products, the expression levels of p63 and p73 are regulated by different mechanisms. This might be responsible for the discordant biological roles of p63 and p73 in development, as well as their deviant expression characteristics in cancer. Oncogene (2003 Oncogene ( ) 22, 5686-5693. doi:10.1038 Keywords: p53; p63; p73; E2F; TGFb; cell density p53 suppresses the formation of malignant tumors largely through its ability to induce apoptosis. At least to a large extent, this is accomplished by the direct activation of target genes (Vogelstein et al., 2000; Vousden and Lu, 2002) . In addition to p53, mammalian cells contain two homologous genes, p63 and p73. These genes give rise to the expression of proteins that are highly similar to p53 in structure and function. In particular, p63 and p73 proteins are capable of inducing p53-responsive genes, and they can elicit programmed cell death (Jost et al., 1997; Kaghad et al., 1997; Osada et al., 1998; Yang et al., 1998) .
Despite these similarities, a number of functional differences were found between p53, p63, p73, and their respective gene products. p53, but not p73 and p63, interacts with a number of viral oncoproteins Higashino et al., 1998; Marin et al., 1998; Prabhu et al., 1998; Roth et al., 1998; Reichelt et al., 1999; Roth and Dobbelstein, 1999; Steegenga et al., 1999; Wienzek et al., 2000) . Unlike p53, the p73 and p63 genes do not represent bona fide tumorsuppressor genes, and tumors rarely contain p73 or p63 mutations (Mai et al., 1998; Nomoto et al., 1998; Takahashi et al., 1998; Hagiwara et al., 1999; Nishi et al., 1999) . Rather, p63 is amplified in a large proportion of squamous cell carcinomas (Hibi et al., 2000) , and p73 is frequently overexpressed in various malignancies, including breast carcinoma and neuroblastoma (Tokuchi et al., 1999; Zaika et al., 1999; Douc-Rasy et al., 2002; Zaika et al., 2002) . p53À/À mice develop tumors with high frequency (Donehower et al., 1992) , whereas p73À/À and p63À/À mice do not (Mills et al., 1999; Yang et al., 1999 . Gene targeting also revealed that the functions of p63 and p73 not only differ from those of p53, but also from each other. While p73À/À mice present defects in their nervous and immune systems , p63À/À mice lack multilayered squamous epithelia (Yang et al., 1999) . These observations clearly indicate that p53 and its relatives have distinct biological functions. Such differences may have their basis in the biochemical properties of the proteins, but they may as well arise from discordant gene expression patterns.
The gene structures of p53 and its homologs are different from each other. Unlike p53, the p63 and p73 genes contain a second transcriptional start site, giving rise to the expression of aminoterminally truncated proteins, DNp63 and DNp73, as opposed to the fulllength proteins that contain transactivation domains, TAp63 and TAp73 . In addition, p63 and p73 can vary at their carboxyterminal ends, due to differential splicing at the 3 0 portion of the mRNA, yielding isoforms such as a, b, etc (De Laurenzi et al., 1998; Yang et al., 1998; Hibi et al., 2000) .
The transactivating (TA) isoforms of p73 are transcriptionally induced by E2F and contribute to E2F-mediated apoptosis (Irwin et al., 2000; Stiewe and Putzer, 2000; Zaika et al., 2001) . In accordance, TAp73 mRNA levels are negatively regulated by transforming growth factor b (TGFb), an antagonist of E2F activity (Irwin et al., 2000) . We and others have recently observed that p53, as well as the TA isoforms of its homologs, can strongly enhance the levels of DNp73 mRNA and DNp73 protein, and that the DNp73 promoter contains a functional p53-responsive element (Grob et al., 2001; Kartasheva et al., 2002; Nakagawa et al., 2002) . Since DNp73 protein species antagonize the activities of p53 and TAp73 (Grob et al., 2001; Kartasheva et al., 2002; Nakagawa et al., 2002; Stiewe et al., 2002; Zaika et al., 2002) , a negative feedback loop is established that regulates p53 and its transcriptionally active homologs.
In contrast to p73, little is known about the regulation of p63. In particular, the question remains whether known stimuli of p73 expression -p53 and E2F activity -also affect the expression of p63. It has been reported that DNp63 proteins and the corresponding mRNA are downregulated upon treatment of keratinocytes by ultraviolet irradiation (Liefer et al., 2000) . Since ultraviolet irradiation induces p53 activity (Perry et al., 1993) , this suggests that the decrease in DNp63 expression may be due to p53. Nevertheless, more direct assays are required to clarify this issue.
We show here that both promoters of p63 differ in their response to p53 and E2F activity, as well as to increased cell density, when compared to p73. Thus, despite their structural similarities, the two genes are regulated differentially, suggesting an explanation for their distinct biological roles.
p53 enhances the expression of DNp73, but not DNp63
To test whether p53 influences the transcription of DNp63, as it does for DNp73, p53 was expressed by an adenovirus vector in human keratinocytes. This cell type was chosen because p63 expression is known to be essential for the development of the epidermis (Yang et al., 1999) , arguing that the regulation of p63 in keratinocytes is physiologically relevant. Both DNp63 and DNp73 mRNA species were detected by reverse transcription and semiquantitative polymerase chain reaction (RT-PCR). The amplification was stopped at different numbers of PCR cycles, and the reaction products were detected on agarose gels. As shown in Figure 1a , the PCR product derived from DNp73 mRNA was much more abundant in the sample prepared from p53-overexpressing cells, indicating that the amount of DNp73 mRNA was strongly increased upon p53 expression, in accordance with our previous results (Kartasheva et al., 2002) . In contrast, the amount of DNp63 mRNA was reduced. The Ubiquitin control was slightly downregulated in the presence of p53, but not nearly as much as DNp63. TAp73 mRNA was not detectable in these cells (but was found in MCF7 and LS174T cells using the same protocol), and TAp63 mRNA levels remained unchanged. Similar results were obtained when cells were treated with camptothecin, a DNA-damaging agent known to activate endogenous p53 (Kartasheva et al., 2002) . Hence, p53 specifically enhances the amount of DNp73 mRNA, but reduces that of DNp63 mRNA. The reduction of DNp63 mRNA was still observed in LS174T cells (derived from prostate carcinoma cells) and MCF7 cells (from breast carcinoma), but was not as pronounced as in keratinocytes, perhaps reflecting a special role of DNp63 repression by p53 for arresting the growth of this cell type.
The levels of p73 and p63 proteins in response to p53 were assessed by immunoblot analysis (Figure 1b) . Again, p73 protein levels were strongly increased upon p53 expression. The size of the detected protein corresponds to DNp73a, as analysed here (Figure 1b ) and previously (Kartasheva et al., 2002) using recombinant p73 proteins. p63 was detected by a monoclonal antibody (clone 4A4) that is widely used to analyse p63 Figure 1 Differential response of DNp63 and DNp73 to p53. (a) p63 and p73 mRNA levels in response to p53. Human keratinocytes (Oligene) were maintained in serum-free keratinocyte media (Oligene) and infected with adenovirus vectors to express b-galactosidase or p53, or were mock-infected as indicated (multiplicity of infection ¼ 500), followed by further incubation in keratinocyte media (Life Technologies). LS174T and MCF7 cells were treated the same way for comparison, using the media RPMI and DMEM, respectively. Similarly, keratinocytes were exposed to camptothecin at 300 nm or 1500 nm concentration, or treated with the corresponding amount of the DMSO solvent. After 24 h, total RNA was isolated from the cells (input). The mRNA from each p63 and p73 isoform was reverse transcribed and PCR-amplified for the indicated numbers of cycles. Viruses: Adenovirus vectors expressing p53 and b-galactosidase have been described (Koch et al., 2001) . Viruses were amplified, the titer was determined and infections were carried out as described (Weigel and Dobbelstein, 2000; Koch et al., 2001) . Semiquantitative RT-PCR: Total RNA was prepared (Trizol Reagent, Life Technologies), followed by RT with Superscript II polymerase (Life Technologies) and PCR amplification with Pfu Turbo DNA polymerase (Stratagene). The PCR cycles consisted of a 3-min denaturation step at 961C, followed by the indicated numbers of cycles at 961C for 30 s, 601C for 30 s, and 701C for 40 s. The primers used for RT and amplification of both p73 mRNA species have been described (Kartasheva et al., 2002) . The primer used for RT of both p63 mRNA species was GTG GCC GAC TTG GCG GTG CTC GAC and the PCR primers were as follows. DNp63 forward: ATG TTG TAC CTG GAA AAC AAT GC, TAp63 forward: TGA ACC ATC AGA AGA TGG TGC GAC, p63 reverse (both TA and DN): CTG GAA GGA CAC GTC GAA ACT GTG. When amplifying Ubiquitin C mRNA, the primer ACT GGG CTC CAC CTC AAG GGT GAT was used for RT, and the primers GTC GCA GCC GGG ATT TGG GTC GCG and GTC TTG CCA GTG AGT GTC TTC ACG for amplification. The reaction products were analysed by agarose gel electrophoresis and ethidium bromide staining. (b) p63 and p73 protein levels in response to p53. Cells treated as in (a) were harvested, and cellular proteins were analysed by immunoblot using antibodies against the indicated proteins. Recombinant proteins derived from transcription and translation in vitro were run on the same gel for size comparison. The corresponding cDNA constructs for p73 were described earlier (Kartasheva et al., 2002) , those for p63 were generously provided by F McKeon. The MYC tags contained within the original p63 constructs were removed by sitedirected mutagenesis. Note that the transduction with adenovirus vectors, even when expressing the b-galactosidase control, generally led to a decrease in p63 levels. From this new baseline, p53 further decreased the amount of p63. Immunoblot: Proteins were separated on SDS polyacrylamide gels and transferred to nitrocellulose, followed by incubation with antibodies in PBS containing 5% milk powder and 0.1% Tween 20. Peroxidase-coupled secondary antibodies (whole immunoglobulin G against murine primary antibodies, F(ab 0 ) 2 fragments to visualize the rabbit antibody to p73a; Jackson) were then detected by chemiluminescence (Pierce). A polyclonal rabbit antibody against p73a (amino acids 450-636) was obtained from BD Pharmingen. Monoclonal mouse antibodies were against p63 (clone 4A4, BD), and against actin (clone C-2, Santa Cruz Biotechnology) Differential regulation of p63 and p73 expression A Waltermann et al expression in human tissue (Cviko et al., 2000; Pellegrini et al., 2001; Quade et al., 2001; Wang et al., 2001) . Its specificity was validated using recombinant p63 proteins obtained by translation in vitro. In contrast to p73, the p63 protein species corresponding to DNp63a was reduced by p53 in human keratinocytes, and the actin control remained largely unchanged. We conclude that p53 increases the intracellular amount of DNp73 protein, but reduces that of DNp63. We consistently noticed that even the addition of an adenovirus vector for b-galactosidase expression led to a decrease of p63 protein levels, compared to mock-infected cells (Figure 1b) . Although we do not know the reason for this phenomenon, it might be due to the onset of a signalling cascade by virus-receptor interactions, or the triggering of a DNA damage response by the presence of virus DNA in the nucleus of transduced cells. The DN isoform of p63 appeared much more abundant than 
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Differential regulation of p63 and p73 expression A Waltermann et al TAp63 (Figure 1b) , although the TA isoform was also expressed and readily detectable at the mRNA level ( Figure 1a) . Perhaps, this may be due to a longer biological half-life of DNp63, when compared to TAp63, in the cells under study.
p53 induces the promoter of DNp73, but not a similar promoter region from DNp63
The differential response of DNp73 and DNp63 to p53 prompted us to analyse the corresponding promoter regions. The genomic region upstream of the 3 0 exon of human p73 was previously cloned and analysed by reporter assays (Kartasheva et al., 2002) . We then created a similar reporter construct comprising the corresponding region of p63. Computer-assisted analysis revealed potential p53-binding sites in both DN promoter regions (Figure 2a ), the sequence of the binding site in the DNp63 promoter region being TAACTTGT-TATTGAAACATGCTC (residues matching the p53-binding consensus, el-Deiry et al., 1992; Zauberman et al., 1993, underlined) . However, when both constructs were cotransfected with a p53 expression plasmid into H1299 cells (p53À/À), only the DNp73 promoter yielded increased luciferase activity, whereas the DNp63 promoter as well as two control promoters were largely unaffected by p53 (Figure 2b ). The TA promoters of p63 and p73 were not found to contain p53-responsive elements in a similar computer-assisted analysis (cf. Figure 4a ), and they were nonresponsive to p53 in reporter assays (data not shown). We conclude that, in contrast to the DNp73 promoter, the analysed genomic region upstream of the DNp63 transcribed region does not display increased promoter activity in response to p53, in agreement with the lack of increased DNp63 mRNA levels upon p53 expression. One might wonder why a reduction of DNp63 mRNA was observed in the presence of p53 (Figure 1a) , whereas no parallel repression by p53 was observed in the reporter assays shown in Figure 2b . The promoter elements responsible for p53-mediated repression could be missing in the reporter construct, or differences in chromatin packaging between chromosomal and plasmid DNA could account for the apparent discrepancy. Finally, DNp63 repression by p53 might be generally less pronounced in H1299 cells than in keratinocytes, as was observed in MCF7 and LS174T cells (Figure 1a) .
TGFb reduces the expression of TAp73, but not that of TAp63
In addition to the DN transcripts of p63 and p73, we were seeking to compare the regulation of the TA mRNA levels. The major previously characterized property of the TAp73 promoter consists in its strong activation by E2F. Since TGFb antagonizes E2F activity, the repression of TAp73 by TGFb was previously taken as indirect evidence for the response of TAp73 expression to E2F (Irwin et al., 2000) . Therefore, we first asked how TGFb affects the expression of p63 when compared to p73. HaCat cells, a human keratinocyte-derived cell line, were chosen for this experiment, since they were previously shown to decrease TAp73 mRNA levels in response to TGFb Analysis of DNp63 and DNp73 promoter activities in response to p53. H1299 cells were transiently transfected with luciferase reporter plasmids containing the promoter sequences of DNp63 and DNp73 (40 ng), a minimal promoter derived from the adenovirus major late promoter (described in Contente et al., 2002) , and the Rous Sarcoma Virus 3 0 long terminal repeat (RSV-LTR) promoter (Roth and Dobbelstein, 1997) . In addition, an expression construct for p53 (pRcCMVp53, Lin et al., 1994) , or the corresponding empty vector plasmid, were cotransfected as indicated. After a 24 h incubation time, luciferase activities were determined. In each experiment, the obtained values were normalized according to the luciferase activity obtained with the RSV-LTR promoter. The results of at least three independent experiments are shown along with the standard deviation. The ratio of luciferase activities obtained in the presence and absence of p53 was calculated for each promoter and is indicated above the columns. Plasmids: The DNp63 promoter region (À558 to þ 262 with respect to the reported transcriptional start site) was amplified from human genomic DNA using the PCR primers CGC ACG CGT CCT ATT TCC CGT ACA TAA TAT GGA TG and GGA AGA TCT GTT AGC TGT AAG ATT GAT CAA TGC. The PCR product was cloned into pGL3-Basic (Promega) using the restriction enzymes MluI and BglII, to obtain pGL3DNp63. A similar plasmid containing the DNp73 promoter region (À969 to À16 with respect to the reported transcriptional start site) has been described previously (Kartasheva et al., 2002) . Cell culture and transfections: H1299 cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Life Technologies) with 10% fetal bovine serum (FBS). Transfections were performed using Lipofectamine 2000 (Life Technologies), followed by luciferase assays (Promega) Differential regulation of p63 and p73 expression A Waltermann et al (Irwin et al., 2000) , and since they readily allow the detection of p63 and p73 mRNA species, each in both isoforms under study. The cells were first allowed to reach confluence, and then trypsinized. From a fraction of the cells, RNA was prepared immediately; the rest was seeded in two dishes at low density for 24 h. One of these samples was left untreated; the other one was treated with TGFb. RNA was isolated from these samples subsequently, and the levels of p63 and p73 mRNA species were determined by semiquantitative RT-PCR. As expected from previous studies, the TAp73 mRNA was markedly increased upon splitting to low density, presumably due to increased E2F activity in cells that resume cycling. However, this effect was reduced by the addition of TGFb to the cells (Figure 3a) . In contrast to p73, changes of either p63 mRNA species were not observed, neither in response to changes in cell density, nor to TGFb. The observed variations in p73 mRNA levels were reflected by p73 protein levels ( Figure 3b ). The relative amounts of the highest molecular weight p73 protein species in the three samples corresponded exactly to those of TAp73 mRNA, and the levels of the second largest p73 protein species corresponded to those of DNp73 mRNA, arguing that these proteins represent the respective translation products. The amounts of p63 and actin proteins remained largely unaffected by TGFb and were moderately reduced at high cell density. Thus, TGFb selectively reduces the expression of TAp73.
High cell density increases the expression of DNp73
Surprisingly, the levels of DNp73 mRNA and the corresponding protein levels were much higher in confluent cells than at low density (Figure 3 ). This cannot be explained by differences in p53 activity, since HaCat cells carry a p53 mutation that abolishes p53-mediated transactivation (Lehman et al., 1993; Datto et al., 1995) . Also, DNp73 mRNA levels were not restored by TGFb, suggesting that the effect of high cell density on DNp73 mRNA is not a result of differential E2F activity. Thus, an unknown p53-independent mechanism is induced by high cell density and increases the expression of DNp73.
E2F-1 induces the promoter of TAp73, but not a promoter region from TAp63
Next, we analysed the TAp63 promoter and its response to E2F. Both the TAp63 and the TAp73 promoter displayed putative E2F-binding sites when subjected to computer-assisted analysis, although such sites were more frequently found in the TAp73 promoter (Figure 4a) . To determine the function of these sites, the genomic region upstream of the human TAp63 transcript was cloned into a luciferase reporter construct. A similar plasmid containing the TAp73 promoter (Stiewe and Putzer, 2000) was kindly provided by B Pu¨tzer. Each of these promoter constructs was transfected into H1299 cells, together with an expression plasmid for E2F-1 (kindly provided by S Gaubatz), followed by luciferase quantification. Only the TAp73 promoter was induced by E2F-1 in this assay, whereas the TAp63 promoter and two control promoters were not (Figure 4b) . Correspondingly, only a TAp73-derived E2F site bound strongly to E2F-1 in electrophoretic p63 and p73 mRNA levels in response to TGFb. HaCat cells were grown to confluence in DMEM/10% FCS and then trypsinized. From a fraction of the cells RNA was prepared immediately; the rest was seeded at low density in duplicate. One of these samples was incubated with a medium containing TGFb (Calbiochem, 0.2 ng/ml); the other one was left untreated as indicated. After 24 h, RNA was prepared (input) and mRNA levels of p63 and p73 were determined as described in the legend to Figure 1a. (b) p63 and p73 protein levels in response to TGFb. Cells were treated as in (a), followed by SDS-PAGE, immunoblot, and staining with antibodies against the indicated proteins, as described in the legend to Figure 1b Differential regulation of p63 and p73 expression A Waltermann et al mobility shift assays, whereas predicted E2F sites from the TAp63 promoter did not ( Figure 5 ). Putative E2F binding sites were also identified in the DN promoter sequences of p63 and p73 (cf. Figure 2a) . However, no response of these promoters to E2F-1 was detected in similar reporter assays (data not shown). We conclude that among all four p63 and p73 promoters analysed, direct response to E2F-1 is unique to TAp73. Taken together, these results indicate that the primary known mechanisms of p73 regulation do not apply to p63. Neither is DNp63 transcription induced by p53, nor is TAp63 repressed by TGFb or induced by E2F-1. Also, cell density affects the expression of DNp73, but not that of DNp63. Thus, the current models of p73 regulation cannot be transferred to p63. Most notably, while TAp73 appears as an essential effector of E2F-1-mediated apoptosis (Irwin et al., 2000; Stiewe and Putzer, 2000; Zaika et al., 2001) , this function cannot be ascribed to TAp63. Similarly, while DNp73 establishes an autoregulatory negative feedback loop to control p53 when the latter is activated (Grob et al., 2001; Kartasheva et al., 2002; Nakagawa et al., 2002) , DNp63 is not part of such a dynamic regulatory mechanism.
In our experiments, DNp63 protein levels were downregulated by p53. This may be due to the moderate reduction of DNp63 mRNA levels by p53, and also to the destabilization of DNp63 protein by p53 that was previously reported (Ratovitski et al., 2001) . In any case, TAp73-promoter TAp63-promoter -1190 TAp63-promoter - to -1176 E2F binding site (MatInspector) E2F binding site (Stiewe et al., 2001) E2F bindingsite (Seelan et al., 2002) - Quandt et al., 1995) . The E2F-binding sites identified previously in the p73TA promoter by other groups (Stiewe and Putzer, 2000; Seelan et al., 2002) are also indicated. (b) Analysis of TAp63 and TAp73 promoter activities in response to E2F-1. Promoter activities were determined by cotransfection of reporter plasmids (40 ng) with an expression plasmid for E2F-1 (30 ng), as described in the legend to Figure 2b . The ratio of luciferase activities obtained in the presence and absence of exogenous E2F-1 was calculated for each promoter and is indicated above the columns. Plasmids: The TAp63 promoter region (À2335 to þ 25 with respect to the transcriptional start site according to Genbank accession number AF124528) was amplified from human genomic DNA using the PCR primers TTG GTA GAG CTC GAG GAT AGC TTG AGT CCA GCA G and CTT AGA GCT AGC CCT TCA ACT GTC TTT GAT ATC AAC G. The PCR product was cloned into pGL3-Basic (Promega) using the restriction enzymes NheI and SacI, to obtain pGL3TAp63. A reporter plasmid containing the human TAp73 promoter (Stiewe and Putzer, 2000) was generously provided by B Pu¨tzer Figure 5 Analysis of putative E2F-binding sites in the TAp63 promoter, in comparison to the TAp73 promoter. Double-stranded DNA corresponding to the indicated putative E2F-binding sites in the TA promoters of p63 and p73 was radiolabelled and incubated with a mixture of E2F-1 and DP-2. An antibody against E2F-1 was added as indicated to yield a supershift. In the case of the TAp73 promoter element, a mutant was used as an additional negative control. Electrophoretic mobility shift assay: We generated E2F-1 and DP-2 by in vitro transcription and translation using T7 RNA polymerase and rabbit reticulocyte lysate (Promega). These preparations (2.5 ml) were incubated with 2-ml sheared salmon sperm DNA (0.25 mg/ml), 7 ml EMSA buffer (25 mm Tris-HCl pH 7.5, 130 mm NaCl, 3mm KCl, 5% bovine serum albumin, 12% glycerol, 1 mm dithiothreitol) and, when indicated, 2 ml monoclonal antibody against E2F-1 (SantaCruz; 200 mg/0.1 ml), for 10 min at 231C. Subsequently, we added 1 ng of the radiolabelled DNA probe and continued the incubation for 30 min at 231C. The reaction mixes were then separated at 41C on a native 5% polyacrylamide gel with 0.5 TBE as a running buffer, followed by autoradiography using a Bioimager (Fuji). We generated the probes by annealing the oligonucleotides indicated below to each other and performing fillin reactions (exo À Klenow enzyme, MBI Fermentas) including a-32 P-dCTP. The oligonucleotides had the following sequences: TAp73 (À155 to À148) forward: GAT CCT GCC TTC CCG CGC GC; TAp73 (À155 to À148) reverse: GGG CAA CAG CGC GCG GGA AGG CAG; mutant TAp73 (À155 to À148) forward: GAT CCT GCC TTC CAT CGC GC; mutant TAp73 (À155 to À148) reverse: GGG CAA CAG CGC GAT GGA AGG CAG; TAp63 (À309 to À302) forward: GAT CTC CAG CTC CAA ATT GC; TAp63 (À309 to À302) reverse: GGG CAA CAG CAA TTT GGA GCT GGA; TAp63 (À1190 to À1176) forward: GAT CTT TTT TTC CCC CTG TT; TAp63 (À1190 to À1176) reverse: GGG CAA CAA ACA GGG GGA AAA AAA Differential regulation of p63 and p73 expression A Waltermann et al it can be concluded that p53 activity results in reduced levels of DNp63, as opposed to increased levels of DNp73. We propose that, in contrast to the negative feedback function of DNp73 induction, the decrease of DNp63 levels in response to p53 may contribute positively to the suppression of cell growth by p53.
The distinct biological functions of p63 and p73 are most evident by the entirely different phenotypes displayed by p73À/À and p63À/À mice (Mills et al., 1999; Yang et al., 1999 . Moreover, p63 and p73 are each overexpressed in different tumor species (Tokuchi et al., 1999; Zaika et al., 1999 Zaika et al., , 2002 Hibi et al., 2000; Douc-Rasy et al., 2002) . On the other hand, the biochemical functions of p63 and p73 proteins are similar, since both act comparably on p53-responsive promoters (Jost et al., 1997; Kaghad et al., 1997; Osada et al., 1998; Yang et al., 1998) . Thus, it is tempting to speculate that the differential regulation of p63 and p73 expression accounts for the majority of their differences in biological function.
Since the regulation of p63 is clearly distinct from p73, it becomes an immediate question by what mechanisms the transcription of p63 is regulated. It is particularly intriguing that p63 expression in adult mammals is largely confined to the basal layer of squamous epithelia. Indeed, the detection of p63 has been reported to identify the stem cells of this tissue (Pellegrini et al., 2001) , and targeted disruption of p63 virtually abolishes the formation of squamous epithelia (Yang et al., 1999) . Thus, highly tissue-specific mechanisms govern the expression of p63, and these regulatory mechanisms are essential for the development of squamous epithelia.
We observed that high cell density strongly and specifically augments the amounts of DNp73 mRNA and DNp73 protein in a p53-independent fashion (cf. Figure 3 ). An earlier report describes an increase of p73 mRNA (without specifying TA or DN isoforms) upon the addition of calcium to human keratinocytes (De Laurenzi et al., 2000) . Perhaps, calcium-induced differentiation and high cell density increase DNp73 expression by similar mechanisms. However, differentiation led to a decrease in p63 expression (De Laurenzi et al., 2000) , whereas high cell density did not (Figure 3) . It is known that keratinocytes respond to changes in cell density with altered gene expression. For instance, confluent HaCat cells secrete insulin-like growth factor binding protein-6 (IGFBP-6) (Kato et al., 1995) and upregulate the expression of keratinocyte growth factor receptors (Capone et al., 2000) . Moreover, the subcellular localization of b-catenin is regulated by cell density in HaCat cells (Dietrich et al., 2002) . The overexpression of DNp73 is apparently another hallmark of keratinocyte density. Since DNp73 is a regulator of transcription, its increased levels might serve to transduce the extracellular signals that arise from enhanced cell density into an adaptive change of the cellular transcription pattern.
p63 and p73 encode highly similar products. In contrast, these genes respond differentially to at least three modulators, that is, p53, E2F, and cell density. Differential regulation might explain the distinct roles of p63 and p73 in development and tumor growth.
